COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Drug treatment of disseminated non small cell lung cancer  (NSCLC) is an actual  issue today.  Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of  gefitinib (G.)  therapy in patients with non operable NSCLC who hase no E...

Full description

Bibliographic Details
Main Authors: S. A. Protsenko, A. V. Rudakova, F. V. Moiseyenko, E. V. Levchenko, D. E. Matsko, A. О. Ivantsov, I. I. Semenov, A. G. Ievleva, N. V. Mitushkina, A. V. Togo, A. V. Novik, E. N. Imyanitov, V. M. Moiseyenko
Format: Article
Language:English
Published: Bashkir State Medical University 2017-01-01
Series:Креативная хирургия и онкология
Subjects:
немелкоклеточный рак легкого
гефитиниб
анализ «затраты/эффективность»
Online Access:https://www.surgonco.ru/jour/article/view/111

Internet

https://www.surgonco.ru/jour/article/view/111

Similar Items